Aprea Therapeutics (APRE) Stock: Buy, Sell, or Hold?
APRE - Aprea Therapeutics, Inc. Common stock
$0.54
-0.01 (-0.92%)
▼
5d:
-8.15%
30d:
-31.18%
90d:
-14.1%
HOLD
MODERATE Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 11, 2026
18d
Get Alerted When APRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: APRE shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: APRE shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: APRE is currently trading at $0.54, which is considered oversold relative to its 30-day fair value range of $0.58 to $0.76.
Technical Outlook: Technically, APRE is in a downtrend. Immediate support is located at $0.51, while resistance sits at $0.66.
Market Sentiment: APRE scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.30 (+509.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, APRE is in a downtrend. Immediate support is located at $0.51, while resistance sits at $0.66.
Market Sentiment: APRE scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.30 (+509.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.58 -
$0.76
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 509.3% below Wall St target ($3.30)
- CAUTION: 5-day price weakness (-8.1%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.58 -
$0.76
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.51
Resistance Level
$0.66
Current Trend
Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.34
Wall Street Target
$3.30
(+509.3%)
Revenue Growth (YoY)
-98.4%
Share & Embed Analysis
Last updated: October 23, 2026 10:49 AM ET
Data refreshes hourly during market hours. Next update: 11:49 AM
Data refreshes hourly during market hours. Next update: 11:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is APRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 62 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 44 HOLD |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 57 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 66 BUY |
